CYP2B6 Polymorphisms and Suicidal Behaviour in HIV Patients on Efavirenz Therapy

Alejandro Arenas-Pinto's supplementary data from a 2026 global case-control study investigates the association between CYP2B6-based genetic risk scores, efavirenz plasma levels, and suicidal behaviour in people living with HIV. The dataset includes 74 cases and 146 controls matched from several global antiretroviral therapy clinical trials linked to the INSIGHT network. It contains results from conditional logistic regression analyses, including odds ratios for genetic metabolizer status and drug exposure.

Use Cases

• Assessing the association between genetic metabolizer status and suicidal behaviour based on CYP2B6-based GRS categories.
• Analyzing the relationship between efavirenz plasma levels and adverse psychiatric outcomes.
• Investigating the prevalence of pre-existing psychiatric conditions and recreational drug use in a clinical trial cohort.
• Conducting matched case-control studies on drug safety using genetic and pharmacokinetic data.

Strengths

• Data is derived from a matched case-control study with 74 cases and 146 controls from global clinical trials.
• Includes specific measurements of efavirenz and its metabolites (8-hydroxy-EFV and 7-hydroxy-EFV) in plasma.
• Provides calculated odds ratios with confidence intervals for genetic and exposure associations.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 24.0 KB file size suggests a very limited scope, likely containing summary results rather than raw patient-level data.

Provenance

Source

Alejandro Arenas-Pinto via figshare.

Collection Method

Matched case-control study from several global antiretroviral therapy (ART) clinical trials linked to the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).

Time Range

null

Freshness

Last updated 2026-04-13 07:31:46; freshness should be verified.

Geography

Global (from multiple global trials).